Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases - Wikidata - wikimedia - TriplyDB

Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases

Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases

http://www.wikidata.org/entity/Q36781280

about

Bone and TNF in rheumatoid arthritis: clinical implications Inflammation, bone loss and fracture risk in spondyloarthritis Glucocorticoid-induced osteoporosis Biologic therapies and bone loss in rheumatoid arthritis.Influence of antiTNF-alpha antibody treatment on fracture healing under chronic inflammation.Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era.Glucocorticoids: bad or safe for the bones?Bone Mineral Density and Fracture Risk in Ankylosing Spondylitis: A Meta-Analysis.Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice.Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture.Rates of non-vertebral osteoporotic fractures in rheumatoid arthritis and postfracture osteoporosis care in a period of evolving clinical practice guidelines.Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs.

P2860

Q26777895-ECF9148B-40C4-4DEA-8DE2-AB3495EEDFAB Q26778258-28A08BB1-2A74-4155-9777-F58CB4FF13F9 Q26778272-BD3989E8-0FE9-448C-AF19-A6B3E09CDC4D Q30243911-946D83E4-4952-473A-A5B2-5ECDD70C257F Q33761069-2D6CAE5F-C6E8-4785-A11A-7AF14216376A Q34168792-91EEA2F9-87A4-49C4-9EE4-7FD6AC485620 Q36246088-7868B2ED-8E37-423A-88B5-40D39441A527 Q38831234-26432009-8559-447E-8AD5-C46EFA73AC1C Q39085876-C4751DD6-49B8-449C-8F2A-9EEE978F00AF Q45150201-A14B3084-793E-4C2A-BE7D-6F24803585DB Q45764017-45EB4863-AFEC-4713-B4E9-B803ACD63C22 Q46671185-81FFA1CB-052D-4BB5-9C8F-21591F2DAE8A Q47110800-EA96B7B0-52B5-4AC2-81A8-584A52D0BF27

P2860

Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases

http://www.wikidata.org/entity/Q36781280

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Initiation of tumor necrosis f ...... umatic and autoimmune diseases

@en

type

label

Initiation of tumor necrosis f ...... umatic and autoimmune diseases

@en

prefLabel

Initiation of tumor necrosis f ...... umatic and autoimmune diseases

@en

P1433

Q36781280-4E569664-2289-4024-9C89-436B0EE7A58D

P1476

Q36781280-407EC1AD-AF9A-4CBB-B54E-0D9D5B7FE037

P2093

Q36781280-012E909B-A0E8-441F-9B43-2D3D2E58DA98

Q36781280-13DCD77B-0F5D-4D59-8357-A74A57C9BA2B

Q36781280-1829D888-3F47-40B6-9102-C32AE76B0753

Q36781280-251A4632-C3FE-47B8-91CE-E97B587E682F

Q36781280-363D11C8-26F3-46C1-BABF-8E2FCFF8E19B

Q36781280-47E0EA82-6578-443C-9D26-5F9DBF039BA3

Q36781280-49EF1F22-FA37-4235-8648-F313D8C23D8D

Q36781280-6C814986-B7EE-4C52-9BE6-A3D7628FB32D

Q36781280-6EBFAD99-7A18-497D-9E7C-9FA52DA75217

Q36781280-724021F0-AE42-43AF-9576-EED49AF6DEE9

P2860

Q36781280-069ACF70-48E8-45F2-9ABA-5296E3B33405

Q36781280-0A013863-226E-42CB-ADB7-D8E472319375

Q36781280-0A1329EA-3963-4282-9D34-0AFE8D7926B8

Q36781280-0AE41DF2-0B80-4265-BE3E-D112A6E56FA5

Q36781280-109FE942-1D94-473E-95F2-37E2C763F6BF

Q36781280-12C9D38C-194D-47C5-A3C8-CDA53BF0B3FF

Q36781280-1E6921FA-66FC-4131-A80D-45072A079689

Q36781280-1F708078-9254-442C-AEEF-E4660260A06A

Q36781280-22AD73D5-36E9-4C6E-AEE7-F81EC7216A16

Q36781280-26F3E926-1B89-4CBF-8397-89B268334ECD

P304

Q36781280-3F609315-25C2-40BC-88D6-8BD0FE912DC1

P31

Q36781280-9F317B62-BD9A-4213-8C8E-676E6926B8CC

P356

Q36781280-2E359F41-258A-44F0-AFF6-D35B31C94E2C

P433

Q36781280-4CD7DEDF-B31B-4F59-83A5-700C5CB097A8

P478

Q36781280-C21B2AFC-0425-47A8-9748-6A0D4A9D0E6E

P577

Q36781280-65D9158F-3D36-4453-9ACD-E7AAA42CFE8A

P698

Q36781280-9E9192F2-9BEC-4F92-8D6B-D89813CF239F

P932

Q36781280-DA5173BC-7B5C-467B-88A8-4AB8322F77DE

P356

P1433

Arthritis Care and Research

P1476

Initiation of tumor necrosis f ...... umatic and autoimmune diseases

@en

P2093

C Michael Stein

http://www.w3.org/2001/XMLSchema#string

Carlos G Grijalva

http://www.w3.org/2001/XMLSchema#string

Daniel H Solomon

http://www.w3.org/2001/XMLSchema#string

Edward F Mitchell

http://www.w3.org/2001/XMLSchema#string

Elizabeth Delzell

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Curtis

http://www.w3.org/2001/XMLSchema#string

Lang Chen

http://www.w3.org/2001/XMLSchema#string

Lisa Herrinton

http://www.w3.org/2001/XMLSchema#string

Liyan Liu

http://www.w3.org/2001/XMLSchema#string

Marie R Griffin

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.

Identification and validation of vertebral compression fractures using administrative claims data.

Rheumatoid arthritis, corticosteroid therapy and hip fracture.

Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis

Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study.

Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction

Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.

P304

1085-1094

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACR.21937

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23281339

http://www.w3.org/2001/XMLSchema#string

P932

3631448

http://www.w3.org/2001/XMLSchema#string